Pacira BioSciences (PCRX) Non Operating Interest Expenses (2010 - 2026)

Pacira BioSciences has reported Non Operating Interest Expenses for 17 years, with the latest figure at $3.6 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses fell 22.85% year-over-year to $3.6 million in Q2 2026; TTM through Jun 2026 was $15.5 million, a 16.91% decrease from a year earlier, with the FY2025 full-year figure at $17.4 million, up 5.29% from the prior year.
• Non Operating Interest Expenses was $3.6 million for Q2 2026 at Pacira BioSciences, down from $3.7 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $11.0 million in Q4 2022, with the low at $3.3 million in Q1 2024.
• Average Non Operating Interest Expenses over 5 years is $5.6 million, with a median of $4.4 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Non Operating Interest Expenses surged 46.98% in 2022, then plunged 69.31% in 2023.
• Over 5 years, Non Operating Interest Expenses stood at $11.0 million in 2022, then sank by 69.31% to $3.4 million in 2023, then jumped by 38.13% to $4.7 million in 2024, then retreated by 16.84% to $3.9 million in 2025, then declined by 6.94% to $3.6 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $3.6 million (Q2 2026), $3.7 million (Q1 2026), and $3.9 million (Q4 2025), per Business Quant data.